Company intelligence

Atlas Bio

As of October 27, 2026, Atlas Bio has raised at least $10M in equity across 1 sourced funding round.

BiotechSee connections →
Last verified Oct 27, 2026

Atlas Bio at a glance

As of
Equity raised
$10M[1]
Across 1 sourced roundDerived
Total funding (reported)
$12.5M[2]
October 2026
Lead investors
Creandum[3]
Seed · October 2026
  1. [1] Equity raised: Sum of the 1 sourced equity round in the funding history below (debt, tender offers and rumored rounds excluded), October 27, 2026
  2. [2] Total funding (reported): Tech Funding News, October 27, 2026
  3. [3] Lead investors: Tech Funding News, October 27, 2026

Is something wrong on this page?

Recent changes

  1. Oct 27, 2026Raised $10M Seed Tech Funding News
  2. Oct 27, 2026First reported total funding: $12.5M Tech Funding News
  3. Oct 27, 2026New investor: Creandum Tech Funding News
  4. Oct 27, 2026Atlas Bio Raises $12.5M To Simulate Drug Trials, Skip Animal Testing Pulse story

Funding history

1 equity event · newest first · sources dated per row
DateRoundAmountValuationLead investorsSource
Oct 27, 2026Seed$10M—
Creandumunverified
WithFirst Momentum VenturesunverifiedLEA Partners
Tech Funding News

Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.

Investors

CreandumFirst Momentum Ventures

Latest Pulse

  1. Atlas Bio Raises $12.5M To Simulate Drug Trials, Skip Animal TestingAtlas Bio, a Basel, Switzerland startup, has raised $12.5M across a pre-seed and seed round led by Creandum to run AI-simulated Phase II drug trials that could let pharma skip animal testing.→

Coverage Timeline

newest first
  1. Oct 27, 2026AIAtlas Bio Raises $12.5M To Simulate Drug Trials, Skip Animal Testing$12.5M Total Raised→

All Coverage

AI
Atlas Bio Raises $12.5M To Simulate Drug Trials, Skip Animal Testing
AI$12.5M Total Raised

Atlas Bio Raises $12.5M To Simulate Drug Trials, Skip Animal Testing

Atlas Bio, a Basel, Switzerland startup, has raised $12.5M across a pre-seed and seed round led by Creandum to run AI-simulated Phase II drug trials that could let pharma skip animal testing.

DEEP DIVE

Related Companies

Same sector
Scribe TherapeuticsIambic TherapeuticsAttovia TherapeuticsApnimedEli LillyRetension Pharmaceuticals

Atlas Bio FAQ

How much has Atlas Bio raised?

Atlas Bio has raised at least $10M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $10M Seed in October 2026, reported by Tech Funding News. Debt financing, tender offers and secondary sales are not counted. Tech Funding News puts total funding at $12.5M (October 2026).

Who invested in Atlas Bio?

Lead investors in Atlas Bio's sourced funding rounds include Creandum. Per round: its October 2026 Seed was led by Creandum.

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data ·